Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
出版年份 2012 全文链接
标题
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
作者
关键词
-
出版物
ONCOGENE
Volume 32, Issue 29, Pages 3420-3431
出版商
Springer Nature
发表日期
2012-08-13
DOI
10.1038/onc.2012.355
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prognostic Value of Survivin in Patients with Non-Small Cell Lung Carcinoma: A Systematic Review with Meta-Analysis
- (2012) Lou Qian Zhang et al. PLoS One
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling of Antibody Production against Xenograft-released Proteins by Protein Microarrays Discovers Prostate Cancer Markers
- (2011) Flip H. Jansen et al. JOURNAL OF PROTEOME RESEARCH
- Novel Therapeutic Targets in Non-small Cell Lung Cancer
- (2011) Filip Janku et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- (2011) N. Sunaga et al. MOLECULAR CANCER THERAPEUTICS
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology
- (2011) A E J Rogers et al. ONCOGENE
- Distinct Roles of Bcl-2 and Bcl-Xl in the Apoptosis of Human Bone Marrow Mesenchymal Stem Cells during Differentiation
- (2011) Lisa Oliver et al. PLoS One
- Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus
- (2011) C. Ekman et al. RHEUMATOLOGY
- Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis
- (2011) Jun Wu et al. ARTHRITIS RESEARCH & THERAPY
- PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells
- (2010) Giridhar Mudduluru et al. BIOLOGY OF THE CELL
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
- (2010) Rachel MA Linger et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- TNF-α, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages
- (2010) Federica Alciato et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival
- (2009) A. Gustafsson et al. CLINICAL CANCER RESEARCH
- Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
- (2009) S. Grosso et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
- (2008) Chih-Chen Hong et al. CANCER LETTERS
- Growth Suppression of Lung Cancer Cells by Targeting Cyclic AMP Response Element-Binding Protein
- (2008) S. Aggarwal et al. CANCER RESEARCH
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
- (2008) Y.-X. Zhang et al. CANCER RESEARCH
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
- (2008) K-Y Tai et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started